Besides rehabilitation approaches with hearing aids, there are no available treatment options for permanent hearing loss; however, significant contributions to the state of the science has been made at the drug discovery level, and with first-in-kind clinical trials, along with significant resources being allocated in the pursuit of more options for those with hearing loss. In fact, there are more than 40 pharmaceutical and biotechnology companies developing inner ear therapies and potential drug delivery systems. This session will present an overview of the hearing loss therapeutic landscape. We will review groundbreaking clinical trials completed, in progress, and on the horizon. The studies reviewed will include gene therapies along with preventative, enhancement, and regenerative medicine approaches. The review will empower clinicians to be aware of the most recent developments and be conscious of the evolving future landscape of treatment and management of hearing loss. Clinicians have an important role to play, both in educating their patients about the current state of novel therapies, and in partnering in the development and evaluation of these promising interventions.
After this session, attendees will be able to:
1. Describe at least (3) novel treatment approaches underway to prevent, enhancement, or regenerate and treat hearing loss.
2. Describe the drug discovery path from translation into practice, including the need for animal model experiments, FDA-regulated clinical trials, and then on to marketing.
3. Identify at least two (2) resources that can be referenced by clinicians or shared with patients on current clinical trials and possible novel therapies.